Japan To Establish iPS Medical Research Safety Guidelines
This article was originally published in PharmAsia News
Executive SummaryA research team at the Ministry of Health, Labor and Welfare is drafting guidelines addressing safety issues for using induced pluripotent stem cells in regenerative medicine. The guidelines will standardize issues related to generating and managing iPS cells for clinical studies; the purpose is to minimize adverse effects and carcinogenic risks. The Ministry aims to establish formal guidelines within 2010. It will be the world's first safety guidelines targeting iPS cells. (Click here for more - Japanese language
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.